Download AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy and more Lecture notes Immunology in PDF only on Docsity!
Tumor Immunology and Immunotherapy
October 5 - 6, 2021 | Virtual Special Conference AACR Special Conference: Tumor Immunology and Immunotherapy Program as of 11/22/2021 4:58 PM Conference Cochairs: Johanna A. Joyce, University of Lausanne, Lausanne, Switzerland Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, TX Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY
TUESDAY, OCTOBER 5, 2021
10 : 00 AM- 12 : 00 PM Plenary Session 1 : Immunometabolism Session Chair: Johanna A. Joyce, University of Lausanne, Lausanne, Switzerland 10:00 AM-10:25 AM Unconventional ER stress response pro-tumorigenic polarization and survival in TAMs Ping Chih Ho, Ludwig Institute, Lausanne, Switzerland 10:25 AM-10:50 AM Tumor microenvironment metabolism in T cell differentiation and dysfunction Greg M. Delgoffe, University of Pittsburgh, Pittsburgh, PA 10:50 AM-11:15 AM How metabolism shapes tumor-immune interactions and anti-tumor immunity Marcia Haigis, Harvard Medical School, Boston, MA 11:15 AM-11:30 AM Oncolytic adenoviruses expressing metabolic targets can improve viro- immunotherapy with bispecific T cell engagers through reducing acidosis in an in vitro model* Arthur Dyer, University of Oxford, Oxford United Kingdom 11:30 AM-11:4 5 AM The co-expression of VISTA and TIGIT on cytotoxic T cells defines subpopulation with altered immunometabolism* Cassandra Gilmour, Cleveland Clinic Lerner Research Institute, Cleveland, OH 11:45 AM- 12 : 00 PM Immuno-reactive cancer organoid models to examine microbiome metabolite effects on immune checkpoint blockade efficacy* Ethan Shelkey, Wake Forest Baptist Medical Center, Winston-Salem, NC 12 : 00 PM- 12 : 15 PM Break 12 : 15 PM- 1 : 45 PM Plenary Session 2 : Advances in Immune Cell Engineering Session Chair: Johanna A. Joyce, University of Lausanne, Lausanne, Switzerland
Tumor Immunology and Immunotherapy
October 5 - 6, 2021 | Virtual Special Conference AACR Special Conference: Tumor Immunology and Immunotherapy Program as of 11/22/2021 4:58 PM 12: 15 PM-12: 40 PM Engineering enhanced persistence and anti-tumor function for therapeutic human T cells Caroline Arber, Lausanne University Hospital, Epalinges, Switzerland 12: 40 PM-1: 05 PM CAR NK Cells: The future of cancer immunotherapy Rafet Basar, The University of Texas MD Anderson Cancer Center, Houston, TX 1: 05 PM-1: 30 PM Chimeric antigen receptor macrophages for the treatment of solid tumors Saar Gill, University of Pennsylvania, Philadelphia, PA 1: 30 PM-1: 45 PM CRISPR-mediated PTPN2 deletion in CAR T cells enhances anti-tumor efficacy* Xin Du, University of Melbourne, Melbourne, VIC, Australia 1 : 45 PM- 2 : 00 PM Break 2:00 PM-3:15 PM Plenary Session 3: COVID-19 Immunology in Cancer Patients Session Chair: Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas 2:00 PM-2:25 PM Impact of immunotherapy on COVID-19 immunity: Insights from checkpoint blockade in cancer Alexander Huang, University of Pennsylvania, Philadelphia, PA 2:25 PM-2:50 PM Adaptive immune dysregulation in cancer patients with SARS-CoV-2 infection Santosha Vardhana, Memorial Sloan Kettering Cancer Center, New York, NY 2:50 PM-3:15 PM TBD 3: 1 5 PM- 3 : 3 0 PM Break 3 : 3 0 PM-5: 0 0 PM Opening Keynote Lectures Session Chairs: Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, New York 3 : 3 0 PM-4: 1 5 PM Mapping myeloid programs that control tumor immunity Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, NY 4: 1 5 PM-5: 0 0 PM Next generation CAR T cells to overcome resistance Crystal L. Mackall, Stanford University, Stanford, CA
Tumor Immunology and Immunotherapy
October 5 - 6, 2021 | Virtual Special Conference AACR Special Conference: Tumor Immunology and Immunotherapy Program as of 11/22/2021 4:58 PM 12: 40 PM-1: 05 PM Targeting tumor associated macrophages for cancer therapy Jennifer L. Guerriero, Brigham and Women’s Hospital, Boston, MA 1: 05 PM-1: 30 PM Immune suppression in cancer and strategies for its reversal Rosandra Kaplan, National Cancer Institute/National Institutes of Health, Bethesda, MD 1: 30 PM- 1 : 45 PM Context is everything: Microbiota-specific T follicular helper cells in colorectal cancer* Abigail Overacre-Delgoffe, University of Pittsburgh School of Medicine, Pittsburgh, PA 1 : 45 PM-2: 00 PM Macrophage promotion of anti-androgen resistance in prostate cancer bone disease* Binzhi Qian, University of Edinburgh, Edinburgh, United Kingdom 2 : 00 PM- 2 : 15 PM Break 2 : 15 PM-3: 30 PM Plenary Session 6 : Technology and Systems Biology Session Chair: Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas 2: 15 PM-2: 40 PM The power of ONE: Immunology in the age of single cell genomics Ido Amit, Weizmann Institute of Science, Rehovot, Israel 2: 40 PM- 3 : 05 PM Cancer metabolism: Emerging insights from single cell analysis Jason W. Locasale, Duke University, Durham, NC 3 : 05 PM-3: 30 PM Mapping the dynamics of immunotherapy to quantify tumor antigenicity Grégoire Altan-Bonnet, National Cancer Institute, Bethesda, MD 3: 30 PM- 3 : 45 PM Break 3:45 PM-5:15 PM Plenary Session 7: Combinatorial Studies to Overcome Resistance to Immunotherapy Session Chairs: Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, New York 3 : 45 PM-4: 10 PM What does not kill it makes it stronger: Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy
Tumor Immunology and Immunotherapy
October 5 - 6, 2021 | Virtual Special Conference AACR Special Conference: Tumor Immunology and Immunotherapy Program as of 11/22/2021 4:58 PM Anna C. Obenauf, Research Institute of Molecular Pathology, Vienna, Austria 4: 10 PM-4: 35 PM Understanding responses to cancer therapy: The tissue is the issue, the scoop is in the poop, and you are what you eat Jennifer A. Wargo 4: 35 PM-5: 00 PM Immunotherapy for melanoma: Checkpoint blockade combinations Jedd D. Wolchok 5: 00 PM-5: 15 PM Inhibition of MEK1/2 overcomes resistance to aPD-1 blockade in pancreatic ductal adenocarcinoma through modulation of NETosis in tumor-associated neutrophils* Brian Herbst, Johns Hopkins, Baltimore, MD *Short talk from proffered abstract
